Kodiak Sciences Inc · NASDAQ:KOD

Kodiak Sciences — 56th Annual Scientific Meeting of the Retina Society (October 2023)

20 slides from Kodiak Sciences's conference presentation, Oct 13, 2023

  1. Slide 1: Tarcocimab tedromer (KSI-301) 5 mg for RVO: One-year outcomes of Phase 3 BEACON Study

    Tarcocimab tedromer (KSI-301) 5 mg for the treatment of RVO: One-year primary efficacy, durability, and safety outcomes of the Phase 3 BEACON Study Ankoor R. Shah, M.D. Medical and Surgical Retina Specialist Retina Consultants of Texas - Retina Consultants of America on behalf of the BEACON Investig

  2. Slide 2: Disclosures

    Disclosures This presentation will discuss IRB/IEC approved research of an investigational medicine. Ankoor Shah has the following financial interests or relationships to disclose: Regeneron (C) Notal Vision (C) Apellis (O) RegenexBio (C) C= Consultant | R= Research Support | O= Ownership/Stock Opti

  3. Slide 3: KSI-301 (tarcocimab tedromer) and Antibody Biopolymer Conjugates (ABCs)

    KSI-301 (tarcocimab tedromer) and Antibody Biopolymer Conjugates (ABCs) + = ANTIBODY BIOPOLYMER CONJUGATE lgG1 Anti-VEGF Antibody Branched, Optically Clear, High Molecular Weight Phosphorylcholine Polymer KSI-301 (tarcocimab tedromer) is an anti-VEGF ABC that blocks all VEGF-A isoforms 3

  4. Slide 4: Tarcocimab Q8W demonstrated non-inferiority to aflibercept Q4W in mean BCVA

    Tarcocimab Q8W demonstrated non-inferiority to aflibercept Q4W in change in BCVA from baseline to Week 24 in BRVO patients and all RVO patients, with 4 vs 6 doses Mean BCVA Over Time in BRVO 80 Tarcocimab Q8W 76.6 ETDRS Letters Mean BCVA: 75 Aflibercept Q4W 76.5 70 65 60 55 0 1 4 8 12 16 20 24 Weeks

  5. Slide 5: Study design: fixed dosing then individualized treatment with identical criteria

    After receiving fixed dosing in the first 6 months of the BEACON study, patients transitioned to individualized treatment using identical criteria between the arms in the second 6 months Matched Maintenance phase Individualized Treatment Period SE SA phase Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52

  6. Slide 6: Patient Disposition – discontinuations were low and balanced between groups

    Patient Disposition – discontinuations were low and balanced between groups, with 90% of patients remaining on treatment at Week 48 755 patients screened at 138 sites in US, EU and Israel 568 patients randomized Arm A: Arm B: Tarcocimab Aflibercept n = 284 n = 284 284 patients treated 284 patients t

  7. Slide 7: Baseline Patient Demographics and General Characteristics

    Baseline Patient Demographics and General Characteristics Tarcocimab Aflibercept n=284 n=284 Age, years, mean (SD) 66.0 (11.76) 64.7 (11.32) 141 (49.6) 134 (48.6) Female, n (%) Race, n (%) White 240 (84.5) 245 (86.3) Black or African American 23 (8.1) 17 (6.0) Asian 5 (1.8) 5 (1.8) Other 5 (1.8) 6 (

  8. Slide 8: Baseline Ocular Characteristics

    Baseline Ocular Characteristics – tarcocimab treated patients started at a slightly higher baseline BCVA Tarcocimab Aflibercept Parameter n=284 n=284 RVO Type, n (%) BRVO 220 (77.5) 218 (76.8) CRVO 64 (22.5) 66 (23.2) BRVO All Patients BRVO All Patients n=220 n=284 n=218 n=284 BCVA, ETDRS Letters, m

  9. Slide 9: Comparable visual and anatomical outcomes in BRVO patients (fixed dosing)

    Tarcocimab achieved comparable visual and anatomical outcomes in BRVO patients, irrespective of the treatment paradigm used 80 Mean BCVA over time 76.6 (10.3) (ETDRS Letters) 75 76.5 (11.2) Mean BCVA 70 65 60 55 0 1 4 8 12 16 20 24 28 32 36 40 44 48 600 Mean CST Over Time Mean CST (µm) 500 400 279.6

  10. Slide 10: Comparable outcomes in BRVO patients through individualized dosing

    Tarcocimab achieved comparable visual and anatomical outcomes in BRVO patients, irrespective of the treatment paradigm used 80 80 over time Mean BCVA 76.6 (10.3) 75.6 (11.6) (ETDRS Letters) 75 75 76.5 (11.2) 76.6 (10.8) Mean BCVA 70 70 65 65 60 60 55 55 0 1 4 0 18 4 12 8 16 12 20 16 24 20 28 24 32 2

  11. Slide 11: Comparable outcomes in All RVO patients (fixed dosing)

    Similarly, tarcocimab achieved comparable visual and anatomical outcomes in All RVO patients, irrespective of the treatment paradigm used 80 Mean BCVA over time 75.4 (12.3) 75 (ETDRS Letters) 74.7 (12.1) Mean BCVA 70 65 60 55 0 1 4 8 12 16 20 24 28 32 36 40 44 48 600 Mean CST Over Time Mean CST (µm)

  12. Slide 12: Comparable outcomes in All RVO patients through individualized dosing

    Similarly, tarcocimab achieved comparable visual and anatomical outcomes in All RVO patients, irrespective of the treatment paradigm used 80 80 Mean BCVA over time 75.4 (12.3) 75 75 74.6 (12.3) (ETDRS Letters) 74.7 (12.1) 74.3 (13.4) Mean BCVA 70 70 65 65 60 60 55 55 0 1 4 0 18 4 12 8 16 12 20 16 24

  13. Slide 13: Treatment burden distribution through 48 weeks favored tarcocimab

    Treatment burden distribution through 48 weeks had minimal overlap, favoring tarcocimab in both BRVO and All RVO patients 78% of tarcocimab 93% of aflibercept patients received 5 or patients received 6 or Median number of fewer doses over 1 year more doses over 1 year injections through Week 48 50%

  14. Slide 14: After only 4 initiating doses, about half needed no additional injections

    After only 4 initiating doses in the first 6 months, approximately half of tarcocimab- treated patients required no additional injections in the second 6 months Median number of injections through Week 24 6 6 5 4 4 3 2 1 0 Tarcocimab Aflibercept Q8W Q4W BRVO & BRVO & All RVO All RVO 14

  15. Slide 15: Treatment distribution from Week 24 to Week 48

    After only 4 initiating doses in the first 6 months, approximately half of tarcocimab- treated patients required no additional injections in the second 6 months Median number of injections Treatment distribution from Week 24 to Week 48 through Week 24 60% 6 6 Tarcocimab treated patients had a ~30% h

  16. Slide 16: Safety: tarcocimab was well-tolerated, with low rates of adverse events

    Safety: tarcocimab was well-tolerated, with low rates of adverse events Tarcocimab Aflibercept Adverse Events (AEs) up to Week 48 n=284 n=284 Ocular - Study Eye Subjects with any ocular AE 119 (41.9%) 113 (39.8%) Subjects with any ocular serious AE (SAE) 6 (2.1%) 1 (0.4%) Subjects with any Injection

  17. Slide 17: Rates of common ocular adverse events were low

    Rates of common ocular adverse events were low. Cataract events were low and comparable between groups. Tarcocimab Aflibercept Common Ocular Adverse Events (AEs) up to Week 48a n=284 n=284 Subjects with any AE in the Study Eye 119 (41.9%) 113 (39.8%) Conjunctival haemorrhage 24 (8.5%) 22 (7.7%) Eye

  18. Slide 18: Rates of intraocular inflammation were low in both treatment groups

    Rates of intraocular inflammation were low in both treatment groups Tarcocimab Aflibercept Intraocular Inflammation in Study Eye up to Week 48 n=284 n=284 Subjects with at Least 1 Intraocular Inflammation AE* 7 (2.5%) 2 (0.7%) Tarcocimab Aflibercept Endophthalmitis in Study Eye up to Week 48 n=284 n

  19. Slide 19: Conclusions

    Conclusions Dosed head-to-head, tarcocimab After transitioning to as needed retreatment using identical criteria between the arms, tarcocimab matched the efficacy of aflibercept while maintaining tarcocimab’s signature demonstrated the durability advantage Conclusions same efficacy Treatment burden

  20. Slide 20: Thank you to all BEACON investigators and site staff

    Thank you to all BEACON investigators and site staff Czech Republic: Oftex S.R.O., Vseobecna Fakultni Nemocnice V Praze; France: Centre Paradis Monticelli, Centre Hospitalier Universitaire de Bordeaux - Hôpital Pellegrin, Centre Hospitalier Intercommunal de Créteil, Fondation Rothschild, CHRU Dijon

Kodiak Sciences — 56th Annual Scientific Meeting of the Retina Society (October 2023) on 6ix